Pharmaceutical for preventing and treating HIV infection characterized by combining integrase inhibitor and Anti-HIV drug

A pharmaceutical composition combining HIV-1 integrase inhibitors with other anti-HIV drugs addresses drug resistance by providing strong anti-HIV activity and effective treatment against resistant strains, enhancing treatment efficacy.

JP2025134871APending Publication Date: 2025-09-17SHIONOGI & CO LTD
38 Cites 0 Cited by

Patent Information

Application Number
JP2025104041
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-28
Filing Date
2025-06-19
Publication Date
2025-09-17

AI Technical Summary

Technical Problem

Existing anti-HIV drugs face challenges with side effects and the emergence of drug-resistant viruses, necessitating the development of compounds with different mechanisms of action to effectively treat and prevent HIV infection, including strains resistant to current treatments.

Method used

A pharmaceutical composition combining compounds with HIV-1 integrase inhibitory activity and anti-HIV activity, utilizing specific bicyclic or higher carbamoylpyridone derivatives and pyridone derivatives with heterocyclic side chains, along with other anti-HIV drugs like polymerase inhibitors and protease inhibitors, to create a synergistic effect against drug-resistant strains.

Benefits of technology

The combination provides strong anti-HIV activity, suppresses the emergence of drug-resistant HIV strains, and is effective against mutant strains resistant to existing drugs, offering a comprehensive treatment and prevention strategy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide pharmaceuticals useful for the prevention or treatment of HIV infection.SOLUTION: Provided is a pharmaceutical for preventing or treating HIV infection, comprising: (A) a compound represented by formula (I): (where, ring A is a non-aromatic heterocycle; ring B is a benzene ring or a pyridine ring; Q is -NHC(O)- or the like; R1 is each independently halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is alkyl or haloalkyl; R4 is hydrogen or alkyl; and n is an integer of 1 to 3), or a pharmaceutically acceptable salt thereof, in combination with (B) a compound having anti-HIV activity or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art